Jiangsu Yahong Meditech Valuation
Is 688176 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 688176 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 688176 (CN¥7.61) is trading below our estimate of fair value (CN¥13.59)
Significantly Below Fair Value: 688176 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 688176?
Key metric: As 688176 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 688176's PS Ratio? | |
|---|---|
| PS Ratio | 28.5x |
| Sales | CN¥149.71m |
| Market Cap | CN¥4.27b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 19.3x |
| Enterprise Value/EBITDA | -6.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 688176's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.1x | ||
688091 Shanghai Yizhong Pharmaceutical | 35.1x | n/a | CN¥9.4b |
300534 Gansu Longshenrongfa Pharmaceutical IndustryLTD | 2.7x | n/a | CN¥2.9b |
603439 Guizhou Sanli PharmaceuticalLtd | 2.7x | 21.8% | CN¥5.6b |
688073 Bide Pharmatech | 3.7x | 14.6% | CN¥4.0b |
688176 Jiangsu Yahong Meditech | 28.5x | 43.3% | CN¥4.3b |
Price-To-Sales vs Peers: 688176 is expensive based on its Price-To-Sales Ratio (28.5x) compared to the peer average (11.6x).
Price to Sales Ratio vs Industry
How does 688176's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
600664 Harbin Pharmaceutical Group | 0.6x | n/a | US$1.33b |
000411 Zhejiang Int'l GroupLtd | 0.2x | n/a | US$803.42m |
600781 FUREN Group PharmaceuticalLtd | 0.3x | n/a | US$66.91m |
002435 Changjiang Runfa Health Industry | 0.2x | n/a | US$63.75m |
| 5 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 688176 is expensive based on its Price-To-Sales Ratio (28.5x) compared to the CN Pharmaceuticals industry average (3.6x).
Price to Sales Ratio vs Fair Ratio
What is 688176's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 28.5x |
| Fair PS Ratio | 12.3x |
Price-To-Sales vs Fair Ratio: 688176 is expensive based on its Price-To-Sales Ratio (28.5x) compared to the estimated Fair Price-To-Sales Ratio (12.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CN¥7.61 | CN¥8.80 +15.6% | 9.1% | CN¥9.60 | CN¥8.00 | n/a | 2 |
| Nov ’25 | CN¥6.81 | CN¥12.29 +80.4% | 34.9% | CN¥16.57 | CN¥8.00 | n/a | 2 |
| Oct ’25 | CN¥6.60 | CN¥12.29 +86.1% | 34.9% | CN¥16.57 | CN¥8.00 | n/a | 2 |
| Sep ’25 | CN¥5.30 | CN¥12.29 +131.8% | 34.9% | CN¥16.57 | CN¥8.00 | n/a | 2 |
| Aug ’25 | CN¥5.20 | CN¥12.29 +136.2% | 34.9% | CN¥16.57 | CN¥8.00 | n/a | 2 |
| Jul ’25 | CN¥5.25 | CN¥12.29 +134.0% | 34.9% | CN¥16.57 | CN¥8.00 | n/a | 2 |
| Jun ’25 | CN¥6.02 | CN¥12.29 +104.1% | 34.9% | CN¥16.57 | CN¥8.00 | n/a | 2 |
| May ’25 | CN¥6.62 | CN¥12.29 +85.6% | 34.9% | CN¥16.57 | CN¥8.00 | n/a | 2 |
| Apr ’25 | CN¥7.00 | CN¥16.54 +136.2% | 0.2% | CN¥16.57 | CN¥16.50 | n/a | 2 |
| Mar ’25 | CN¥6.74 | CN¥16.54 +145.3% | 0.2% | CN¥16.57 | CN¥16.50 | n/a | 2 |
| Feb ’25 | CN¥6.89 | CN¥16.54 +140.0% | 0.2% | CN¥16.57 | CN¥16.50 | n/a | 2 |
| Jan ’25 | CN¥10.78 | CN¥16.54 +53.4% | 0.2% | CN¥16.57 | CN¥16.50 | n/a | 2 |
| Dec ’24 | CN¥11.10 | CN¥16.54 +49.0% | 0.2% | CN¥16.57 | CN¥16.50 | n/a | 2 |
| Nov ’24 | CN¥11.57 | CN¥16.54 +42.9% | 0.2% | CN¥16.57 | CN¥16.50 | CN¥6.81 | 2 |
| Oct ’24 | CN¥11.19 | CN¥16.54 +47.8% | 0.2% | CN¥16.57 | CN¥16.50 | CN¥6.60 | 2 |
| Sep ’24 | CN¥10.85 | CN¥16.54 +52.4% | 0.2% | CN¥16.57 | CN¥16.50 | CN¥5.30 | 2 |
| Aug ’24 | CN¥12.08 | CN¥21.14 +75.0% | 0.6% | CN¥21.27 | CN¥21.00 | CN¥5.20 | 2 |
| Jul ’24 | CN¥11.69 | CN¥21.14 +80.8% | 0.6% | CN¥21.27 | CN¥21.00 | CN¥5.25 | 2 |
| Jun ’24 | CN¥13.43 | CN¥21.14 +57.4% | 0.6% | CN¥21.27 | CN¥21.00 | CN¥6.02 | 2 |
| May ’24 | CN¥16.65 | CN¥21.14 +26.9% | 0.6% | CN¥21.27 | CN¥21.00 | CN¥6.62 | 2 |
| Apr ’24 | CN¥14.36 | CN¥21.14 +47.2% | 0.6% | CN¥21.27 | CN¥21.00 | CN¥7.00 | 2 |
| Mar ’24 | n/a | CN¥21.14 0% | 0.6% | CN¥21.27 | CN¥21.00 | CN¥6.74 | 2 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Sichuan Kelun Pharmaceutical
CN¥51.1b
Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.
2422
CN¥32.72
7D
7.3%
1Y
15.1%
China Resources Double-Crane PharmaceuticalLtd
CN¥21.4b
China Resources Double-Crane Pharmaceutical Co.,Ltd.
600062
CN¥21.32
7D
2.5%
1Y
10.5%
China Resources Sanjiu Medical & Pharmaceutical
CN¥59.1b
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
999
CN¥45.11
7D
-1.3%
1Y
19.5%